Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2018

View Archived Issues

Patient enrollment ongoing in first-in-human trial of PF-06939926

Sun Biopharma initiates first-line combination study of SBP-101 with gemcitabine and nab-paclitaxel

FDA gives fast track status to Ensysce's PF-614

Zika virus vaccine candidate from Takeda obtains FDA fast track designation

Trial results support safety and activity of carotuximab + sorafenib in hepatocellular carcinoma

ASPH marker possibly useful for CRC screening

EMA committee recommends approval of Lamzede for alpha-mannosidosis

United Neuroscience to develop vaccine to prevent chronic traumatic encephalopathy

GSK-2256098/trametinib combination lacks activity in phase II PDAC study

Innate Pharma and MedImmune collaborate to study IPH-5401 with durvalumab

Chinese authorities approve clinical trials of ZKAB-001

First patient with DLBCL enrolled in phase II study of Cellectar's CLR-131

FDA awards RMAT designation to Abeona Therapeutics' EB-101

Regeneron studies long-term safety and efficacy of evinacumab in patients with HoFH

BL-8040 therapy impacts immune cell populations in pancreatic cancer patients

FDA issues complete response letter for Linhaliq NDA

Pfizer files for approval of lorlatinib in Japan

Bristol-Myers Squibb presents novel ROCK inhibitors

Leo Pharma divulges RORG ligands for psoriasis

Almac Discovery discloses new Wee1 inhibitors

Duke University patents APC-containing vaccines for cancer

Ibentrus identifies new fusion proteins for cancer

ProMetic Life Sciences finalizes design of phase III study of PBI-4050 in IPF

FDA accepts revefenacin NDA

Johnson & Johnson reviews pipeline progress of fourth quarter 2017

Phase I data presented for JCAR-017 in B-NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...